New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
18:35 EDTRUBI, TXMD, BWLD, YELP, TRN, NUVA, X, ECYT, ZLTQ, AFL, ICPT, WB, AMGN, SQNM, EXAM, RNG, PNRA, MOVE, FB, TWTR, NCR, EW, AEGROn The Fly: After Hours Movers
UP AFTER EARNINGS: Panera Bread (PNRA), up 1.3%... Zeltiq Aesthetics (ZLTQ), up 28.1%... Rubicon Project (RUBI), up 12.5%... RingCentral (RNG), up 11%... Endocyte (ECYT), up 10.5%... Aegerion Pharmaceuticals (AEGR), up 9.4%... Examworks (EXAM), up 8.8%... U.S. Steel (X), up 7.3%... Edwards Lifesciences (EW), up 7.2%... Sequenom (SQNM), up 7.5%... NuVasive (NUVA), up 5.6%... NCR Corp. (NCR), up 3.5%... Amgen (AMGN), up 4% after reporting quarterly results and announcing that it will reduce its global workforce by 12%-15%... Trinity Industries (TRN), up 2.8%... Twitter (TWTR), up 29.1% after reporting better than expected second quarter results as well as third quarter and fiscal 2014 guidance above analyst expectations. NOTABLE: Weibo Corp (WB), up 5.5%; Yelp (YELP), up 3.6%; Facebook (FB), up just under 1%, respectively, following Twitter's second quarter results. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 2.5% following upgrade to Buy from Neutral at Nomura. DOWN AFTER EARNINGS: Buffalo Wild Wings (BWLD), down 10.6%... Move Inc. (MOVE), down 3.5%... Aflac (AFL), down 4% after reporting second quarter results and guidance for third quarter and fiscal 2014. ALSO LOWER: TherapeuticsMD (TXMD), down marginally after filing to sell $40M in common stock.
News For PNRA;ZLTQ;RUBI;RNG;ECYT;AEGR;EXAM;X;EW;SQNM;NUVA;NCR;AMGN;TRN;TWTR;WB;YELP;FB;ICPT;BWLD;MOVE;AFL;TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 4, 2014
09:37 EDTXActive equity options trading
Active equity options trading according to Track Data: AAPL ALTR P BIDU AMZN TSLA X NFLX TWTR WMT
09:22 EDTICPTIntercept endpoint for NASH trial achievable, says Summer Street
Subscribe for More Information
09:18 EDTTWTRTwitter CEO trusts sell 141,730 shares
Subscribe for More Information
07:53 EDTNUVANuVasive price target raised to $53 from $44 at Brean Capital
Subscribe for More Information
06:43 EDTFBFacebook and ESET announce partnership to fight malware
Subscribe for More Information
06:16 EDTICPTIntercept initiated with an Outperform at RW Baird
Target $258.
December 3, 2014
16:30 EDTSQNMOn The Fly: Closing Wrap
Stocks on Wall Street opened quietly and trading remained muted through another session. Despite a host of economic data, including the Fedís Beige book report, the market moved in a narrow range, albeit toward record levels. The Fedís report confirmed the economy continues to improve, but at a slow pace. ECONOMIC EVENTS: In the U.S., Automatic Data Processing reported private payrolls increased 208k in November, versus expectations for 222K. Q3 nonfarm productivity grew 2.3%, versus expectations for an increase of 2.4%. Markit's final services PMI for November dropped to 56.2, which was below the 56.3 November flash print and down from October's 57.1 reading. The Institute for Supply Management's composite non-manufacturing index jumped to 59.3 in November from 57.1 in October, beating expectations for it to remain unchanged. The Federal Reserve Beige Book stated that the country's economy continued to expand in October and November. Consumer spending rose in most areas and the employment situation improved in many areas, while demand for nonfinancial services rebounded and lending held steady or increased, districts reported to the central bank. COMPANY NEWS: Carbonite (CARB) jumped $2.68, or 22.79%, to $14.44 after J2 Global (JCOM) offered to acquire all of the company's outstanding shares for $15.00 per share in cash. Carbonite's board will carefully "review and consider the offer," the company announced following its receipt of the unsolicited takeover bid. Investors reacted favorably to J2 Global's offer, sending its shares up $3.36, or 5.9%, to $60.33 as well. MAJOR MOVERS: Among the notable gainers was Sequenom (SQNM), which rose 72c, or 23.61%, to $3.77 after the company and a unit of Illumina (ILMN) agreed to settle all their pending infringement claims. Also higher was UTi Worldwide (UTIW), which jumped $2.34, or 20.28%, to $13.88 after Bloomberg, citing people with knowledge of the matter, reported that the company could reach an agreement to sell itself to Denmark-based DSV A/S as soon as this month. Among the noteworthy losers was Puma Biotechnology (PBYI), which sunk $27.33, or 12.15%, to $197.67 after the company delayed the filing for neratinib from the first half of 2015 to Q1 of 2016. Also lower were Class B shares of Brown-Forman (BF.B), which fell $3.75, or 3.91%, to $92.25 after the maker of Jack Danielís and other spirits reported lower than expected earnings and lowered its FY15 EPS view. INDEXES: The Dow rose 33.07, or 0.18%, to 17,912.62, the Nasdaq gained 18.66, or 0.39%, to 4,774.47, and the S&P 500 added 7.78, or 0.38%, to 2,074.33.
16:00 EDTTWTR, FBOptions Update; December 3, 2014
iPath S&P 500 VIX Short-Term Futures down 45c to 26.52. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX C GILD RIG ABX according to Track Data.
15:51 EDTAMGNAmgen confirms FDA approval for BLINCYTO
Amgen announced that the FDA has granted approval of BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes the first FDA-approved bispecific CD19-directed CD3 T-cell engager antibody construct product, and the first single-agent immunotherapy to be approved for the treatment of patients with Ph- relapsed or refractory B-cell precursor ALL, the company said. BLINCYTO has a BOXED WARNING in its product label regarding Cytokine Release Syndrome and Neurological Toxicities.
13:13 EDTAMGNAmgen drug for rare form of ALL approved by FDA
The FDA said it approved Blincyto to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, an uncommon form of ALL. Blincyto carries a boxed warning alerting patients and health care professionals that some clinical trial participants had problems with low blood pressure and difficulty breathing at the start of the first treatment, or other side effects in the nervous system. The FDA approved Blincyto with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care providers about the serious risks and the potential for preparation and administration errors. Blincyto is marketed by Amgen.
12:39 EDTSQNMOn The Fly: Midday Wrap
Subscribe for More Information
11:44 EDTICPTIntercept slips after outlining possible endpoints for upcoming study
Subscribe for More Information
11:35 EDTFBStocks with call strike movement; ANF FB
Abercrombie & Fitch (ANF) May 35 call option implied volatility decreased 13% to 34, Facebook (FB) March 82.5 call option implied volatility increased 2% to 32 according to IVolatility.
10:47 EDTSQNMSequenom settlement positive but reflected in stock price, says Ladenburg
Ladenburg views the settlement reached between Sequenom (SQNM) and Illumina (ILMN) as a near-term positive for Sequenom that gives more clarity on the competitive landscape, lowers its legal expenses and brings in needed capital. However, the firm believes the near-term financial benefit is reflected in the stock's valuation and maintains its Neutral rating on Sequenom shares.
09:35 EDTSQNMActive equity options trading
Subscribe for More Information
09:23 EDTSQNMOn The Fly: Pre-market Movers
Subscribe for More Information
07:25 EDTICPTIntercept price target lowered to $99 from $125 at FBR Capital
FBR Capital lowered its price target for shares of Intercept Pharmaceuticals to $99 after the company updated guidance for the Phase III program for OCA in NASH. FBR thinks Intercept's plan to propose co-primary endpoints increases the efficacy risk of the program, especially if a lower dose is included to minimize itching and lipid excursions. The firm thinks shares are worth about $70 without the NASH opportunity. It keeps an Underperform rating on the stock.
07:14 EDTFBBusiness Insider to hold a conference
Business Insider IGNITION 2014 Conference is being held in New York on December 1-3 with webcasted company presentations to begin on December 3 at 8 am; not all company presentations may be webcasted. Webcast Link
07:09 EDTSQNMPiper Jaffray to hold a conference
Subscribe for More Information
06:07 EDTSQNMIllumina and Sequenom end patent dispute with partnership in prenatal testing
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use